Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus

Clinical Therapeutics
Thomas Danne

Abstract

Every year, approximately 70,000 children aged<15 years develop type 1 diabetes mellitus (DM) worldwide. Achieving glycosylated hemoglobin control is a very important aim, but quality-of-life concerns for the child and the family should also have high priority in the management of pediatric DM. This review outlines some of the issues involved in treating type 1 DM in children and adolescents, as well as the use of rapid-acting insulin analogues in basal-bolus therapy and continuous subcutaneous insulin infusion pumps. This review article was based on a presentation at a satellite symposium entitled "Realising the Value of Modern Insulins: Reaching Further with Rapid-Acting Insulin Analogues "that was convened during the XIXth World Diabetes Congress, December 3, 2006, in Cape Town, South Africa. Treating children and adolescents with DM is a challenge that should not be ignored. Furthermore, DM in children is quite different from that in adults. Numerous factors have to be taken into account when evaluating treatment for children with DM in comparison with treatment for adult DM: sleep patterns; unpredictable activities, especially eating behaviors; limited size of injection sites, making it difficult to rotate injections; high...Continue Reading

Citations

Jun 23, 2009·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·S Ben BecherZ Fitouri
Oct 26, 2010·Diabetes Technology & Therapeutics·Satish GargAnastasia Rodionova
Jan 6, 2009·Diabetes, Obesity & Metabolism·B SheldonJ Wright
Oct 12, 2013·Indian Journal of Pediatrics·Vandana Jain
Jan 7, 2014·Expert Opinion on Biological Therapy·M Loredana Marcovecchio, Francesco Chiarelli
May 12, 2012·Endocrinology and Metabolism Clinics of North America·William V Tamborlane, Kristin A Sikes
Jun 23, 2011·Diabetes/metabolism Research and Reviews·Simon HellerOlga Kordonouri
Dec 16, 2010·Pharmaceutics·Rong Shi, Hartmut Derendorf
Jul 14, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Anne PetersWilliam V Tamborlane
Jul 30, 2010·Expert Opinion on Pharmacotherapy·Alberto VerrottiFrancesco Chiarelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.